In this Issue:
RD ±carfilzomib in relapsed MM
Dose escalation of SAR650984, with RD, in relapsed/refractory MM
Daratumumab with RD in relapsed/refractory MM
Elotuzumab plus RD in relapsed/refractory MM
Ixazomib maintenance following ixazomib-RD induction in previously untreated MM
Tracking human myeloma cell therapeutic resistance
Ibrutinib ±dexamethasone in relapsed/refractory MM
Serum FLC for evaluating response in light chain MM
Weekly carfilzomib, cyclophosphamide and dexamethasone in newly diagnosed MM
Effect of age on outcomes in newly diagnosed MM treated with RD
Please login below to download this issue (PDF)